HEI-AMEDIUM SIGNALOPPORTUNITY10-K

HEI-A delivered strong across-the-board financial performance with revenue growing 16.3% and net income surging 34.3%, while maintaining consistent customer concentration patterns.

The company demonstrated excellent operational leverage with net income growth (+34.3%) significantly outpacing revenue growth (+16.3%), indicating improving margins and efficiency. The strong cash flow generation (+39% to $934.3M) provides ample resources for growth investments, evidenced by the 25% increase in capital expenditures.

Comparing 2025-12-22 vs 2024-12-19View on EDGAR →
FINANCIAL ANALYSIS

HEI-A posted robust growth across all key metrics, with revenue advancing 16.3% to $4.5B while net income surged 34.3% to $690.4M, demonstrating strong operational leverage. Operating cash flow jumped 39% to $934.3M, far outpacing the 25% increase in capital expenditures, indicating healthy cash generation and disciplined investment. The balance sheet strengthened with stockholders' equity growing 18.4% to $4.3B and cash increasing 29%, though current liabilities also rose 25%, suggesting growth-driven working capital needs.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+39%
$672.4M$934.3M

Operating cash flow surged 39% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+34.3%
$514.1M$690.4M

Net income grew 34.3% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
+28.8%
$108.3M$139.5M

Cash grew 28.8% — improving liquidity position supports investment and shareholder returns.

Current Liabilities
Balance Sheet
+25.3%
$663.9M$832.0M

Current liabilities rose 25.3% — increased short-term obligations, watch current ratio.

Capital Expenditure
Cash Flow
+25.1%
$58.3M$72.9M

Capex increased 25.1% — ongoing investment in capacity or infrastructure for future growth.

Operating Income
P&L
+23.6%
$824.5M$1.0B

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Stockholders Equity
Balance Sheet
+18.4%
$3.6B$4.3B

Equity base grew 18.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Revenue
P&L
+16.3%
$3.9B$4.5B

Revenue growing 16.3% — solid top-line momentum, watch margins for quality of growth.

Current Assets
Balance Sheet
+14.3%
$2.1B$2.4B

Current assets grew 14.3% — improving short-term liquidity or inventory/receivables build.

SG&A Expense
P&L
+13.3%
$677.3M$767.5M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2025-12-22
PRIOR — 2024-12-19
ADDED
Changes in and Disagreements w ith Accountants on Accounting and Financial Disclosure 113 Item 9A.
and their collective subsidiaries, accounted for 70%, 68% and 60% of our net sales in fiscal 2025, 2024 and 2023, respectively.
and its subsidiaries, accounted for 30%, 32% and 40% of our net sales in fiscal 2025, 2024 and 2023, respectively.
The ETG derived approximately 51%, 51% and 49% of its net sales in fiscal 2025, 2024 and 2023, respectively, from the sale of products and services to U.S.
An expendable is generally a part which is used up and replaced as opposed to being repaired for further use.
+7 more — sign up free →
REMOVED
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 113 Item 9A.
and their collective subsidiaries, accounted for 68%, 60% and 57% of our net sales in fiscal 2024, 2023 and 2022, respectively.
and its subsidiaries, accounted for 32%, 40% and 43% of our net sales in fiscal 2024, 2023 and 2022, respectively.
The ETG derived approximately 51%, 49% and 56% of its net sales in fiscal 2024, 2023 and 2022, respectively, from the sale of products and services to U.S.
An expendable is generally a part which is used and not thereafter repaired for further use.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
IRIXHIGHIRIX demonstrated a dramatic operational turnaround with revenue surging 283% wh...
2026-04-02
CSAIHIGHCSAI underwent a dramatic financial transformation with revenue growing 271% to ...
2026-03-31
PLMKWHIGHPLMKW has entered into a definitive business combination agreement with Controll...
2026-03-31
LXEOHIGHLXEO achieved significant clinical milestones with positive interim data and reg...
2026-03-30
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →